Unité de cryothérapie VPULSE

Disponible en deux versions (acc. 1) :

- Sans coussin de compression séquentielle VPulse

- Avec 2 coussins de compression séquentielle VPulse

Voici la liste complète des accessoires disponibles en option, nous demandé un devis par mail svp.

Le système VPULSE est un appareil médical révolutionnaire conçu pour offrir la combinaison unique de trois traitements de rééducation :

1. Compressothérapie séquentielle intermittente visant à prévenir les embolies pulmonaires (EP) et les thromboses veineuses profondes (TVP) d’origine nosocomiale
2. Compressothérapie dynamique intermittente visant à réduire les oedèmes
3. Cryothérapie contrôlée contribuant à une compliance élevée tout en soulageant la douleur et en réduisant les in ammations

Chaque fonction est essentielle pour garantir l’e cacité de la rééducation postopératoire et la prévention des complications. La continuité des soins et le respect des instructions n’ont jamais été aussi simples et accessibles pour les patients.

Unité de cryothérapie VPULSE®

VPULSE improves patient outcomes, reduces the total cost of the orthopedic episode and increases patient satisfaction to deliver more time well spent.

VPULSE helps patients achieve complete, comfortable recoveries through delivery of three distinct therapies:

• Rapid impulse calf compression to help prevent Deep Vein Thrombosis (DVT)
• Motorized cold therapy to help reduce operative site discomfort and inflammation
• Wound compression to further help reduce operative site inflammation

• Product Features*

  Lowers Risk of Venous Thromboembolism (VTE): VPULSE lowers incidence of VTE after major orthopedic surgery compared to pharmacological prophylaxis. VTE is the leading factor for hospital readmission following major orthopedic surgery and the most common preventable cause of hospital death.

  Provides Possible Alternative to Anticoagulants: VPULSE offers physicians another option to help tailor preventative care to patient risk and provides an alternative for patients contraindicated for anticoagulants.

  Provides Convenient Home Therapy: As hospital stays continue to shorten, VPULSE provides a solution for patients to take home and keep. This allows facilities to offer mechanical DVT prophylaxis for the 2-3 weeks patients need it most, without the hassle of renting or servicing equipment.

  Improves Patient Experience: Combining three therapies into one convenient device optimizes patient comfort during recovery. With motorized cold therapy and accompanying water bottles, patients avoid the hassle of frequently switching out ice cubes or gel packs.

  Improves Compliance: The added comfort of cold and compression therapies may increase patient compliance compared to DVT prophylaxis alone. A removable data card records patient compliance to enable physician monitoring.

  Lowers Total Cost: Bundled payment of care initiatives are driving single payment for an orthopedic episode within 30 days of surgery, including costly DVT readmissions. By reducing DVT-related expenses and potentially reducing costs for anticoagulant regimes or compression device rental programs, VPULSE helps reduce the total cost of the episode.

  DVT Definitions and Statistics

  Deep vein thrombosis (DVT) refers to the development of blood clots, or thrombi, within a deep vein. Typically it occurs in the thigh or calf and can develop after any major surgery. Symptoms may include pain, swelling and skin discoloration, or no signs at all. DVT risk is greatest between two and five days after surgery, with a second peak risk period occurring about 10 days after surgery—after the patient has been discharged.1 A consecutive pulmonary embolism, or PE, can occur when a clot breaks free and travels through the veins and lodges in the lungs. PE has been reported to occur in over one third of DVT patients and frequently causes sudden death.2

  The National Center for Health Statistics estimates that DVT is an underlying cause of death for up to 100,000 people annually in the U.S. Estimates place the number of persons affected as high as 900,000. Between 10 and 30 percent will die within one month of diagnosis, and one third will have a recurrence within 10 years. Survivors may have lasting ramifications and chronic respiratory and cardiovascular issues.3 Without either mechanical or pharmacological prevention, DVT with no obvious symptoms will develop in 40 to 60 percent of patients undergoing total hip and knee arthroplasty.2 These numbers suggest a very real need for prevention.

  1 Deep Vein Thrombosis – OrthoInfo – AAOS. January 2009. Available at: orthoinfo.aaos.org/topic.cfm?topic=a00219

  2 The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008. Available at: www.ncbi.nlm.nih.gov/books/NBK44178/

  3 Centers for Disease Control. 2015. Available at: www.cdc.gov/ncbddd/dvt/data.html